Oct 04, 2021 / 12:30PM GMT
Operator
My name is Christie, and I will be your conference facilitator today for Amgen's conference call from EADV inflammation. (Operator Instructions)
I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.
Arvind Sood - Amgen Inc. - VP of IR
Thank you, Christie. Good morning, everybody. Thanks for joining us this morning.
So over the weekend, we announced positive data from a Phase II study of AMG 451 at the European Academy of Dermatology and Venereology. AMG 451, as you know, is a potential first-in-class anti-OX40 fully human monoclonal antibody that's being developed for the treatment of moderate to severe atopic dermatitis.
Now in this time -- Christie, there's a background noise. Okay. All right. Let's see if this works. All right. So in addition to reviewing this data in some detail, I would like to invite you to engage in a broader dialogue this morning on all the work that we have done and continue to do to develop a broad presence in inflammation. With ENBREL as a backbone,
Amgen Inc Call to Discuss Clinical Data Being Presented at EADV Transcript
Oct 04, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers